BR112013031759A2 - forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides - Google Patents

forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides

Info

Publication number
BR112013031759A2
BR112013031759A2 BR112013031759A BR112013031759A BR112013031759A2 BR 112013031759 A2 BR112013031759 A2 BR 112013031759A2 BR 112013031759 A BR112013031759 A BR 112013031759A BR 112013031759 A BR112013031759 A BR 112013031759A BR 112013031759 A2 BR112013031759 A2 BR 112013031759A2
Authority
BR
Brazil
Prior art keywords
treatment
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
Prior art date
Application number
BR112013031759A
Other languages
English (en)
Portuguese (pt)
Inventor
Helena Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Astrazeneca Ab
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Bayer Ip Gmbh filed Critical Astrazeneca Ab
Publication of BR112013031759A2 publication Critical patent/BR112013031759A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013031759A 2011-06-29 2012-06-27 forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides BR112013031759A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
BR112013031759A2 true BR112013031759A2 (pt) 2016-12-13

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031759A BR112013031759A2 (pt) 2011-06-29 2012-06-27 forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides

Country Status (16)

Country Link
EP (1) EP2726464A1 (es)
JP (1) JP2014527955A (es)
KR (1) KR20140036230A (es)
CN (1) CN103814015A (es)
AR (1) AR086818A1 (es)
AU (1) AU2012277514A1 (es)
BR (1) BR112013031759A2 (es)
CA (1) CA2839398A1 (es)
IN (1) IN2014MN00023A (es)
MX (1) MX2013014566A (es)
RU (1) RU2013153466A (es)
SG (1) SG195309A1 (es)
TW (1) TW201305115A (es)
UY (1) UY34170A (es)
WO (1) WO2013001294A1 (es)
ZA (1) ZA201309480B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
WO2022114105A1 (ja) * 2020-11-27 2022-06-02 ミライラボバイオサイエンス株式会社 高純度βニコチンアミドモノヌクレオチド（ＮＭＮ）及びその製造方法
CN116283781A (zh) * 2022-12-16 2023-06-23 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
ES2535701T3 (es) 2010-07-21 2015-05-14 Astrazeneca Ab Inhalador
BR112013001342A2 (pt) 2010-07-21 2016-05-17 Astrazeneca Ab dispositivo

Also Published As

Publication number Publication date
IN2014MN00023A (es) 2015-06-12
ZA201309480B (en) 2015-10-28
JP2014527955A (ja) 2014-10-23
SG195309A1 (en) 2013-12-30
KR20140036230A (ko) 2014-03-25
CN103814015A (zh) 2014-05-21
TW201305115A (zh) 2013-02-01
MX2013014566A (es) 2014-09-25
RU2013153466A (ru) 2015-08-10
CA2839398A1 (en) 2013-01-03
WO2013001294A1 (en) 2013-01-03
AR086818A1 (es) 2014-01-22
AU2012277514A1 (en) 2014-01-09
EP2726464A1 (en) 2014-05-07
UY34170A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
BR112015018168A2 (pt) inibidores de rock suaves
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112013031759A2 (pt) forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
BR112014011333B1 (pt) composto, composição farmacêutica e uso do composto de fórmula
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
CL2009000464A1 (es) Compuestos derivados de 3-(n-(azetidin-3-il)metanosulfonilamino)benzamida, actuan en los receptores cannabinoides cb1; procedimiento para prepararlos; composici0n farmaceutica y su uso para tratar o prevenir trastornos psiquiatricos, trastornos cognitivos, enfermedades neurodegenerativas, trastornos del metabolismo, dolor.
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock
BR112015011898A2 (pt) forma cristalina a da chidamida, método para preparar a forma cristalina a da chidamida, uso da forma cristalina a da chidamida, forma cristalina b da chidamida, método para preparar a forma cristalina b da chidamida, uso da forma cristalina b da chidamida e formulação farmacêutica para o tratamento de doenças relacionadas à diferenciação e proliferação celular
DOP2019000172A (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
CL2009000637A1 (es) Compuestos derivados sulfonamida sustituido, antagonista b1r; composición farmacéutica que los comprende; proceso de preparación de los compuestos, y uso en el tratamiento del dolor causado por inflamación, dolor agudo, neuropático, visceral, también en diabetes, migraña, entre otras.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2015000580A1 (es) Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros.
CL2008001325A1 (es) Compuestos derivados de pirazol-piridinona; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar inflamacion, enfermedad de paget, osteoartritis, alzheimer, entre otras enfermedades.
BR112013029416A2 (pt) derivados de indol substituídos para o tratamento de distúrbios imunológicos
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
BR112015007991A2 (pt) derivados de etinila como moduladores da atividade do receptor de mglur5

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]